Compare Stocks: BNTC, FBRX, TSHA, and SNDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$11.02 -3.0%	$12.43	$9.85 ▼ $16.76	$384.41M	0.27	110,103 shs	422,990 shs
FBRX Forte Biosciences	$76.99	$71.39	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
SNDX Syndax Pharmaceuticals	$17.62 -0.3%	$20.15	$12.99 ▼ $25.59	$1.56B	0.37	1.36 million shs	5.18 million shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.64B	1.19	2.55 million shs	9.12 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.99%	-9.60%	-17.64%	-9.30%	-19.56%
FBRX Forte Biosciences	0.00%	0.00%	+0.12%	+331.32%	+543.73%
SNDX Syndax Pharmaceuticals	-0.34%	-3.08%	-15.17%	-7.26%	+19.46%
TSHA Taysha Gene Therapies	-2.71%	0.00%	-21.93%	-21.81%	+73.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$11.02 -3.0%	$12.43	$9.85 ▼ $16.76	$384.41M	0.27	110,103 shs	422,990 shs
FBRX Forte Biosciences	$76.99	$71.39	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
SNDX Syndax Pharmaceuticals	$17.62 -0.3%	$20.15	$12.99 ▼ $25.59	$1.56B	0.37	1.36 million shs	5.18 million shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.64B	1.19	2.55 million shs	9.12 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.99%	-9.60%	-17.64%	-9.30%	-19.56%
FBRX Forte Biosciences	0.00%	0.00%	+0.12%	+331.32%	+543.73%
SNDX Syndax Pharmaceuticals	-0.34%	-3.08%	-15.17%	-7.26%	+19.46%
TSHA Taysha Gene Therapies	-2.71%	0.00%	-21.93%	-21.81%	+73.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.00	117.79% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$42.30	140.07% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	154.37% Upside

Current Analyst Ratings Breakdown

Latest BNTC, FBRX, TSHA, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/15/2026	BNTC Benitec Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/15/2026	BNTC Benitec Biopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
9/15/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$16.00 ➝ $17.00
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
SNDX Syndax Pharmaceuticals	$172.35M	9.06	N/A	N/A	$0.74 per share	23.81
TSHA Taysha Gene Therapies	$9.77M	167.42	N/A	N/A	$0.90 per share	5.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$37.92M	-$0.98	N/A	N/A	N/A	N/A	-28.41%	-27.76%	9/28/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest BNTC, FBRX, TSHA, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2686	N/A	N/A	N/A	N/A	N/A
9/14/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2643	-$0.26	+$0.0043	-$0.26	$13.70 million	N/A
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	34.00	56.82
FBRX Forte Biosciences	N/A	10.01	10.01
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
FBRX Forte Biosciences	77.63%
SNDX Syndax Pharmaceuticals	N/A
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
FBRX Forte Biosciences	4.40%
SNDX Syndax Pharmaceuticals	4.80%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	19	34.88 million	33.21 million	No Data
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
SNDX Syndax Pharmaceuticals	298	88.61 million	84.36 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

BNTC, FBRX, TSHA, and SNDX Headlines

Recent News About These Companies

Wolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)

September 19 at 1:54 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17 at 9:05 AM | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts

September 17 at 3:46 AM | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

August 20, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BNTC, FBRX, TSHA, and SNDX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$11.02 -0.34 (-2.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.00 -0.03 (-0.23%)

As of 09/18/2026 04:14 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Syndax Pharmaceuticals NASDAQ:SNDX

$17.62 -0.06 (-0.34%)

As of 09/18/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$5.02 -0.14 (-2.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.02 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, FBRX, TSHA, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, FBRX, TSHA, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, FBRX, TSHA, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNTC, FBRX, TSHA, and SNDX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Forte Biosciences NASDAQ:FBRX

Syndax Pharmaceuticals NASDAQ:SNDX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, FBRX, TSHA, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, FBRX, TSHA, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, FBRX, TSHA, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNTC, FBRX, TSHA, and SNDX Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Forte Biosciences NASDAQ:FBRX

Syndax Pharmaceuticals NASDAQ:SNDX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools